ACRS

Company Overview — What Does Aclaris Therapeutics, Inc. Do?

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapeutics, Inc. (ACRS) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Neal S. Walker and employs approximately 100 people, headquartered in Malvern, Pennsylvania. With a market capitalization of $501M, ACRS is one of the notable companies in the Healthcare sector.

Aclaris Therapeutics, Inc. (ACRS) Stock Rating — Hold (April 2026)

As of April 2026, Aclaris Therapeutics, Inc. receives a Hold rating with a composite score of 38.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ACRS ranks #1,202 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aclaris Therapeutics, Inc. ranks #90 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ACRS Stock Price and 52-Week Range

Aclaris Therapeutics, Inc. (ACRS) currently trades at $4.04. The stock lost $0.04 (1.0%) in the most recent trading session. The 52-week high for ACRS is $4.89, which means the stock is currently trading -17.4% from its annual peak. The 52-week low is $1.05, putting the stock 284.8% above its annual trough. Recent trading volume was 617K shares, suggesting relatively thin trading activity.

Is ACRS Overvalued or Undervalued? — Valuation Analysis

Aclaris Therapeutics, Inc. (ACRS) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.41x, versus the sector average of 2.75x. The price-to-sales ratio is 41.75x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aclaris Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aclaris Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aclaris Therapeutics, Inc. (ACRS) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -51.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.9% versus the sector average of -33.1%.

On a margin basis, Aclaris Therapeutics, Inc. reports gross margins of 76.2%, compared to 71.5% for the sector. The operating margin is -759.9% (sector: -66.1%). Net profit margin stands at -630.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 19.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ACRS Debt, Balance Sheet, and Financial Health

Aclaris Therapeutics, Inc. has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.36x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $25M.

ACRS has a beta of 0.40, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Aclaris Therapeutics, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Aclaris Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aclaris Therapeutics, Inc. reported revenue of $11M and earnings per share (EPS) of $-0.53. Net income for the quarter was $-53M. Gross margin was 76.2%. Operating income came in at $-64M.

In FY 2025, Aclaris Therapeutics, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.53. Net income for the quarter was $-65M. Gross margin was 73.3%. Revenue grew -58.2% year-over-year compared to FY 2024. Operating income came in at $-76M.

In Q3 2025, Aclaris Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-15M. Gross margin was 83.7%. Revenue grew -24.1% year-over-year compared to Q3 2024. Operating income came in at $-17M.

In Q2 2025, Aclaris Therapeutics, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-15M. Gross margin was 71.0%. Revenue grew -35.8% year-over-year compared to Q2 2024. Operating income came in at $-18M.

Over the past 8 quarters, Aclaris Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $11M. Investors analyzing ACRS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ACRS Dividend Yield and Income Analysis

Aclaris Therapeutics, Inc. (ACRS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ACRS Momentum and Technical Analysis Profile

Aclaris Therapeutics, Inc. (ACRS) has a momentum factor score of 72/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

ACRS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aclaris Therapeutics, Inc. (ACRS) ranks #90 out of 838 stocks based on the Blank Capital composite score. This places ACRS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ACRS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ACRS vs S&P 500 (SPY) comparison to assess how Aclaris Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

ACRS Next Earnings Date

No upcoming earnings date has been announced for Aclaris Therapeutics, Inc. (ACRS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ACRS? — Investment Thesis Summary

Aclaris Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 20/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Price momentum is positive at 72/100, suggesting the trend favors buyers.

In summary, Aclaris Therapeutics, Inc. (ACRS) earns a Hold rating with a composite score of 38.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ACRS stock.

Related Resources for ACRS Investors

Explore more research and tools: ACRS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ACRS head-to-head with peers: ACRS vs AZN, ACRS vs SLGL, ACRS vs VMD.